# Jin Seok Ahn

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/jin-seok-ahn/

## Facts

| Field | Value |
| --- | --- |
| Citations | 23,133 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 72 |
| i10-index | 312 |
| Last Known Institution | Samsung Medical Center |
| OpenAlex ID | https://openalex.org/A5082025437 |
| ORCID iD | 0000-0002-2880-6730 |
| Works | 812 |

## Researcher papers

Showing 12 of 17.

- [Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer](https://scholariq.org/papers/alectinib-versus-crizotinib-in-untreated-i-alk-i-positive-non-small-cell-lung/)
- [Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma](https://scholariq.org/papers/single-cell-rna-sequencing-demonstrates-the-molecular-and-cellular-reprogramming/)
- [Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study](https://scholariq.org/papers/updated-overall-survival-and-final-progression-free-survival-data-for-patients/)
- [Alectinib in Crizotinib-Refractory <i>ALK-</i>Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study](https://scholariq.org/papers/alectinib-in-crizotinib-refractory-i-alk-i-rearranged-non-small-cell-lung-cancer/)
- [DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load](https://scholariq.org/papers/dna-methylation-loss-promotes-immune-evasion-of-tumours-with-high-mutation-and/)
- [Alectinib in Resected <i>ALK</i> -Positive Non–Small-Cell Lung Cancer](https://scholariq.org/papers/alectinib-in-resected-i-alk-i-positive-non-small-cell-lung-cancer/)
- [Osimertinib for Patients With Non–Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)](https://scholariq.org/papers/osimertinib-for-patients-with-non-small-cell-lung-cancer-harboring-uncommon-egfr/)
- [Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial](https://scholariq.org/papers/pembrolizumab-for-patients-with-refractory-or-relapsed-thymic-epithelial-tumor/)
- [The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma](https://scholariq.org/papers/the-impact-of-epstein-barr-virus-status-on-clinical-outcome-in-diffuse-large-b/)
- [Pembrolizumab for the treatment of non-small cell lung cancer](https://scholariq.org/papers/pembrolizumab-for-the-treatment-of-non-small-cell-lung-cancer-2/)
- [Artificial Intelligence–Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non–Small-Cell Lung Cancer](https://scholariq.org/papers/artificial-intelligence-powered-spatial-analysis-of-tumor-infiltrating/)
- [Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non–Small-Cell Lung Cancer: KCSG-LU05-04](https://scholariq.org/papers/multinational-randomized-phase-iii-trial-with-or-without-consolidation/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Researcher university

- [Samsung Medical Center](https://scholariq.org/institutions/samsung-medical-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.